Profile

Identity, professional record and current appointments.

Overview

Professional record at a glance

A concise summary of information supported by the cited public sources. Missing information is treated as unknown, not as a negative finding.

Current roles
11 current organization shown on this profile
Board positions
11 supported by public sources, 0 supplied by the profile owner
Committee roles
Not establishedNo committee role is currently confirmed by the cited sources
Qualifications
Not establishedNo qualification is currently confirmed by the cited sources

Professional narrative

About

Seasoned executive with over 30 years of experience in life sciences and biotechnology, specializing in finance, corporate strategy, and business development. Previously served as CFO and Chief Business Officer at Athira Pharma and VP of Strategy at Amgen.

Sources are shown with the information they support.

Current roles

Appointments & responsibilities

Board appointments

Governance

Board appointments, committee responsibilities and disclosed relationships.

Board and advisory record

Board service

Sources are shown with each role, education record, or credential.

Director

Turn Therapeutics Inc.

Current · start date not disclosed

Confirmed by public sourceView source

Connections

Explore the roles, education and affiliations published in this record.

Turn Therapeutics Inc.

Open Turn Therapeutics Inc. profile →

Director at Turn Therapeutics Inc.

Start not stated → End not stated

current · source reported

Observed: 2026-09-18

Turn Therapeutics …Turn Therapeutics Inc.Andrew Gengos

Dashed lines mark past roles. Select a connection to see its dates and sources.

Relationship map

Connected through the public record

Direct relationships from verified facts and published résumé records. Private connections are excluded.

Direct public links only

Only published affiliations are shown here. Private relationships require authorized access.

Experience

Career history, education, credentials and public contributions.

Published record

Featured coverage

Selected publications and public sources used to establish this profile. Inclusion records provenance; it is not an endorsement.

Source 1 · Sec FilingTTRX 10-K executive officersSupports AI and ML experience, Cybersecurity experience, Executive company, Executive title, Other Company Role, Technology background.Open sourceSource 2 · Sec FilingTERN DEF 14A executive officersSupports Executive company, Executive title.Open source

Basis

Identifiers, sources, dates and record limitations.

Identifiers

Alpha ID
alpha:person:andrew-gengos
Record version
public-0

Sources

Sources and published information

Each item links to the public source used to support it. When sources disagree, the item is clearly marked for review.

AI and ML experience · Source reportedAI and ML experience: not identified in the cited filing1 source
Verification
Source reported
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Board membership · Source reportedServes on the board of Turn Therapeutics Inc.1 source
Verification
Source reported
Confidence
Not stated
Last reviewed
Not stated
Cybersecurity experience · Source reportedCybersecurity experience: not identified in the cited filing1 source
Verification
Source reported
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Executive company · Source reportedExecutive at Terns Pharmaceuticals1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 11, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 11, 2026

Executive company · Source reportedExecutive at Turn Therapeutics Inc.1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Executive title · Source reportedExecutive title: Chief Financial Officer and Treasurer1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 11, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 11, 2026

Executive title · Source reportedExecutive title: Director1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Other Company Role · Source reportedAndrew Gengos is also linked to Terns Pharmaceuticals as Chief Financial Officer.1 source
Verification
Source reported
Confidence
70%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Technology background · Source reportedTechnology background: not identified in the cited filing1 source
Verification
Source reported
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

View all sources4 records
  1. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

    Supports: AI and ML experience · Cybersecurity experience · Executive company · Executive title · Other Company Role · Technology background

  2. https://www.sec.gov/Archives/edgar/data/2023016/000121390026037505/ea0281342-10k_turntherap.htm

    Sec 10k · Tier not stated · Reviewed Sep 14, 2026

    Supports: Director at Turn Therapeutics Inc. (NASDAQ: TTRX)

  3. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 11, 2026

    Supports: Executive company · Executive title

  4. https://www.sec.gov/Archives/edgar/data/2023016/000121390026037505/ea0281342-10k_turntherap.htm

    Public Source · Tier not stated · Reviewed Not stated

    Supports: Board membership